THE USE OF
ANTIRETROVIRAL DRUGS IN PREGNANCY
Zidovudine was the first
agent to be used to prevent the transmission of HIV from a pregnant woman to
her child. It was given to the mother at 14 to 34 weeks’ ges-tation and to the
child for the first 6 weeks of life. Current combination therapies employ
zidovudine with another NRTI and a protease inhibitor.
The teratogenic risk associated
with administration of antiretroviral drugs during the first trimester of
pregnancy is not clear. Women who have not begun therapy prior to becoming
pregnant may consider waiting until after 10 to 12 weeks’ gestation to begin
antiviral treatment. If a woman decides to discontinue antiretroviral therapy
dur-ing pregnancy, all drugs should be stopped and reintro-duced simultaneously
to avoid the development of resist-ance. Pregnant women may be particularly
susceptible to hyperglycemia caused by protease inhibitors.
In the United States, the
Centers for Disease Control recommend that HIV-infected mothers avoid
breast-feeding to prevent the transmission of the virus to their infants. The
risk of this type of vertical trans-mission ranges from 5 to 20%; longer
durations of breast-feeding, mastitis, and abscesses are associated with
increased risk. In developing countries in which safe infant formula is not
readily available, the avoid-ance of breast-feeding can increase the infant’s
risk of death from malnutrition and food-borne infection. The World Health
Organization recommends that under these circumstances exclusive breast-feeding
should be maintained for the first months of life and discontinued when
replacement feeding is acceptable, feasible, af-fordable, sustainable, and
safe.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2024 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.